摘要
目的观察重组人血小板生成素(rh-TPO)与重组人白介素-11(rhIL-11)治疗儿童急性髓系白血病化疗后血小板减少症疗效与不良反应。方法将84例骨髓完全缓解的急性髓系白血病患儿随机分为实验组和对照组;实验组分为两组,一组28例在化疗后应用rh-TPO,一组28例化疗后应用rhIL-11;对照组28例,化疗后不应用升血小板药物。观察各组血小板计数<30×10^(9)/L持续时间、上升到≥50×10^(9)/L及≥100×10^(9)/L所需时间、输注血小板数目及不良反应发生情况。结果在血小板<30×10^(9)/L持续时间比较中,实验组少于对照组,差异有统计学意义(P<0.05);rh-TPO组与rhIL-11组差异无统计学意义(P>0.05)。rh-TPO组、rhIL-11组恢复至≥50×10^(9)/L所需时间,均少于对照组(P<0.05);rh-TPO组少于rhIL-11组,但差异无统计学意义(P>0.05)。rh-TPO组在血小板恢复≥100×10^(9)/L所需时间最短,rhIL-11组次之,对照组最长,三组两两比较,差异均有统计学意义(P<0.05)。与对照组比较,rh-TPO组及rhIL-11组输注血小板数目均少于对照组(P<0.05)。实验组中的rh-TPO组输注血小板数目少于rhIL-11组(P=0.057)。与rhIL-11组比较,rh-TPO组不良反应发生率低,但差异无统计学意义(P>0.05)。结论rh-TPO与rhIL-11均可缩短儿童急性髓系白血病化疗后血小板减少时间,减少血小板输注量,降低不良反应发生率,且rh-TPO更具优势。
Objective To observe the efficacy and adverse reactions of recombinant human thrombopoietin(rh-TPO)and recombinant human interleukin-11(rhIL-11)in the treatment of thrombocytopenia after chemotherapy in children with acute myeloid leukemia.Methods 84 cases of acute myeloid leukemia with complete remission of bone marrow were randomly divided into experimental group and control group.The experimental group was divided into two groups,28 cases were treated with rh-TPO after chemotherapy,the other 28 cases were treated with rhIL-11 after chemotherapy,and 28 cases in control group were not treated with platelet raising drugs after chemotherapy.The duration of platelet count<30×10^(9)/L,the time needed to rise to≥50×10^(9)/L and≥100×10^(9)/L,the number of platelet transfusion and the occurrence of adverse reactions were observed.Results The duration of platelet<30×10^(9)/L in the experimental group was shorter than that in the control group(P<0.05);there was no significant difference between rh-TPO group and rhIL-11 group(P>0.05).In rh-TPO group and rhIL-11 group,the time needed to recover to more than 50×10^(9)/L was less than that in the control group(P<0.05).rh-TPO group was less than rhIL-11 group,but the difference was not statistically significant(P>0.05),The time required for platelet recovery≥100×10^(9)/L in rh-TPO group was the shortest,followed by rhIL-11 group and control group.There were statistical significances among the three groups(P<0.05).Compared with the control group,the number of platelet transfusion in rh-TPO group and rhIL-11 group was less than that in the control group(P<0.05).The number of platelets in rh-TPO group was less than that in rhIL-11 group(P=0.057).Compared with rhIL-11 group,the incidence of adverse reactions in rh-TPO group was lower,but there was no significant difference(P>0.05).Conclusion rh-TPO and rhIL-11 can shorten the time of thrombocytopenia after chemotherapy in children with acute myeloid leukemia,reduce platelet transfusion,decrease the incidence of adverse reactions.rh-TPO has more advantages.
作者
苏于泰
刘炜
马平
管玉洁
宋丽丽
Su Yutai;Liu Wei;Ma Ping(Department of Hematology and oncology,Children's Hospital Affiliated of Zhengzhou University,Zhengzhou 450000)
出处
《中国现代医药杂志》
2021年第6期15-18,共4页
Modern Medicine Journal of China
基金
河南省科技攻关计划项目(编号:212102310036)。
关键词
重组人血小板生成素
重组人白介素11
血小板减少症
化疗
recombinant human thrombopoietin
Recombinant human interleukin 11
Thrombocytopenia Chemotherapy
